Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 9/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | CCKBR | P32239 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045118 | 1.00 | CYP46A1 (0.61) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL29399335 | 1.00 | CYP46A1 (0.61) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL30396114 | 0.83 | CYP46A1 (0.43) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL24517565 | 0.81 | CYP46A1 (0.46) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL6905458 | 0.81 | PDE7A (0.48) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL29378147 | 0.80 | PDE7A (0.41) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL24517450 | 0.80 | CYP46A1 (0.44) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL24296567 | 0.80 | CYP46A1 (0.44) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL1152387 | 0.80 | CYP46A1 (0.43) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL4576238 | 0.80 | CYP46A1 (0.43) | CYP46A1NR1I2NR3C1PGRADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092722-A1 | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolines useful as HIV reverse transcriptase inhibitors | CORBETT JEFFREY W (US) | 2003-05-15 | — | — | US | claimed |
| US-6423718-B1 | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-23 | — | — | US | claimed |
| US-6225317-B1 | REVERSE TRANSCRIPTASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2001-05-01 | — | — | US | claimed |
| US-6124302-A | TREATING HIV INFECTIONS | DUPONT PHARMACEUTICALS (US) | 2000-09-26 | — | — | US | claimed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20100160262-A1 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-24 | — | — | US | disclosed |
| US-7015214-B2 | Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazepine as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| US-20010044540-A1 | Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2001-11-22 | — | — | US | disclosed |
| EP-1131303-A1 | CRYSTALLINE (-)-6- CHLORO-4- CYCLOPROPYLETHYNYL- 4-TRIFLUOROMETHYL- 3,4-DIHYDRO- 2(1H)-QUINAZOLINONE | Du Pont Pharmaceuticals Company (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6225317-B1 | REVERSE TRANSCRIPTASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-6225317-B1 | REVERSE TRANSCRIPTASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-6225317-B1 | REVERSE TRANSCRIPTASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-6204262-B1 | 1,3-Benzodiazepin-2-ones and 1,3-Benzoxazepin-2-ones useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2001-03-20 | — | — | US | disclosed |
| US-6124302-A | TREATING HIV INFECTIONS | DUPONT PHARMACEUTICALS (US) | 2000-09-26 | — | — | US | disclosed |
| WO-2000029390-A1 | CRYSTALLINE (-)-6- CHLORO-4- CYCLOPROPYLETHYNYL- 4-TRIFLUOROMETHYL- 3,4-DIHYDRO- 2(1H)-QUINAZOLINONE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | CYP46A1 580/4885NR1I2 2521/4885NR3C1 1864/4885 |
| US-20010044540-A1 | Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors | QTRT1, NQO2, QTRT2 | CYP46A1 1754/4885NR1I2 726/4885NR3C1 3379/4885 |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CYP46A1 1649/4885NR1I2 4028/4885NR3C1 1352/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | CYP46A1 663/4885NR1I2 2339/4885NR3C1 1476/4885 |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | CYP46A1 2126/4885NR1I2 612/4885NR3C1 451/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CYP46A1 1649/4885NR1I2 4028/4885NR3C1 1352/4885 |
| US-20100160262-A1 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | SIRT1, SIRT3, SIRT2 | CYP46A1 3537/4885NR1I2 2490/4885NR3C1 1591/4885 |
| US-20030092722-A1 | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolines useful as HIV reverse transcriptase inhibitors | DPYD, NQO2, POLRMT | CYP46A1 1440/4885NR1I2 628/4885NR3C1 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.